Therapeutic | Ficlatuzumab |
Target | HGF |
Heavy Chain | QVQLVQPGAEVKKPGTSVKLSCKASGYTFTTYWMHWVRQAPGQGLEWIGEINPTNGHTNYNQKFQGRATLTVDKSTSTAYMELSSLRSEDTAVYYCARNYVGSIFDYWGQGTLLTVSS |
Light Chain | DIVMTQSPDSLAMSLGERVTLNCKASENVVSYVSWYQQKPGQSPKLLIYGASNRESGVPDRFSGSGSATDFTLTISSVQAEDVADYHCGQSYNYPYTFGQGTKLEIK |
100% seqID Fv Structure | None |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G1 |
Highest Clinical Trial (June '19) | Phase-II |
Estimated Status (June '19) | Active |
Recorded Developmental Technology | na |
INN Year Proposed | 2011 |
INN Year Recommended | 2012 |
Companies Involved | AVEO Oncology, AVEO Pharmaceuticals, Dana-Farber Cancer Institute, University of Arizona Cancer Center, University of California at San Francisco |
Conditions Approved | na |
Conditions Active | Head and neck cancer, Non-small cell lung cancer, Acute myeloid leukaemia, Pancreatic cancer |
Conditions Discontinued | Lymphoma, Multiple myeloma, Solid tumours, Glioblastoma |
Notes |